• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒 2 感染癌症患者的急性免疫特征及其后果。

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.

机构信息

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Institute of Biomedical Engineering, University of Oxford, Oxford, UK.

出版信息

Cancer Cell. 2021 Feb 8;39(2):257-275.e6. doi: 10.1016/j.ccell.2021.01.001. Epub 2021 Jan 5.

DOI:10.1016/j.ccell.2021.01.001
PMID:33476581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833668/
Abstract

Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19 non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

摘要

鉴于免疫系统对于癌症的监测和治疗至关重要，我们研究了 SARS-CoV-2 感染癌症患者可能会如何影响其免疫系统。在肿瘤类型、分期和治疗方面存在一定异质性的情况下，暴露于 SARS-CoV-2 的实体瘤癌症患者的免疫特征与 COVID-19 非癌症患者的免疫特征非常相似，表明 SARS-CoV-2 对其产生了显著影响。这种情况在血液系统恶性肿瘤中并不存在，暴露于病毒的患者表现出异质性的体液反应、耗尽的 T 细胞表型以及病毒持续排出的高发生率。此外，尽管康复的实体瘤癌症患者的免疫表型与未暴露于病毒的癌症患者相似，但康复的血液系统癌症患者则表现出明显的、持续存在的免疫后遗症。因此，虽然包括晚期疾病在内的实体瘤癌症患者感染 SARS-CoV-2 后发生免疫失调的风险似乎并不比一般人群更高，但血液系统癌症患者的 SARS-CoV-2 暴露会导致复杂的免疫后果，这可能有助于指导他们的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/6655c4404732/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/4a1281a2d859/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/9d4f18647072/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/bc647714289b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/2dfb4d22e739/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/958d13ba9a0a/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/6d3b9c2c1a80/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/252e5856956b/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/6655c4404732/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/4a1281a2d859/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/9d4f18647072/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/bc647714289b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/2dfb4d22e739/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/958d13ba9a0a/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/6d3b9c2c1a80/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/252e5856956b/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/7833668/6655c4404732/gr7_lrg.jpg

相似文献

1
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.严重急性呼吸综合征冠状病毒 2 感染癌症患者的急性免疫特征及其后果。
Cancer Cell. 2021 Feb 8;39(2):257-275.e6. doi: 10.1016/j.ccell.2021.01.001. Epub 2021 Jan 5.
2
Virological Aspects of COVID-19 in Patients with Hematological Malignancies: Duration of Viral Shedding and Genetic Analysis.血液系统恶性肿瘤患者中 COVID-19 的病毒学特征：病毒脱落持续时间及基因分析
Viruses. 2024 Dec 31;17(1):46. doi: 10.3390/v17010046.
3
CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer.CD8 T 细胞有助于 COVID-19 和血液系统癌症患者的存活。
Nat Med. 2021 Jul;27(7):1280-1289. doi: 10.1038/s41591-021-01386-7. Epub 2021 May 20.
4
Post-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodies.接受SARS-CoV-2单克隆抗体治疗的实体瘤或血液系统恶性肿瘤患者的新冠后免疫力
Immun Inflamm Dis. 2024 Dec;12(12):e70039. doi: 10.1002/iid3.70039.
5
Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease.患有血液肿瘤疾病的严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）患者的病毒长期脱落
In Vivo. 2025 Mar-Apr;39(2):844-850. doi: 10.21873/invivo.13887.
6
Differences of Severe Acute Respiratory Syndrome Coronavirus 2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens Among Adult Inpatients With Coronavirus Disease 2019.新型冠状病毒肺炎成年住院患者痰液与鼻咽拭子标本中 2019 年冠状病毒脱落持续时间的差异。
Chest. 2020 Nov;158(5):1876-1884. doi: 10.1016/j.chest.2020.06.015. Epub 2020 Jun 20.
7
Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.感染前的实验室参数可能可以预测肿瘤患者的 COVID-19 严重程度。
Cancer Med. 2021 Jul;10(13):4424-4436. doi: 10.1002/cam4.4023. Epub 2021 Jun 13.
8
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.癌症患者 COVID-19 疫苗接种后对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的免疫原性和风险：系统评价和荟萃分析。
Eur J Cancer. 2022 Jan;160:243-260. doi: 10.1016/j.ejca.2021.10.014. Epub 2021 Oct 26.
9
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.血液肿瘤患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的血清转换。
J Med Virol. 2021 Jul;93(7):4585-4591. doi: 10.1002/jmv.26886. Epub 2021 Apr 1.
10
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.在预后不良的癌症患者中，SARS-CoV-2 RNA 病毒持续排出和淋巴细胞减少是 COVID-19 的特征。
Cell Death Differ. 2021 Dec;28(12):3297-3315. doi: 10.1038/s41418-021-00817-9. Epub 2021 Jul 6.

引用本文的文献

1
Factors Associated With Mortality in Leukemia and Lymphoma With COVID-19: A National Inpatient Sample Analysis (2020-2021).2019冠状病毒病相关白血病和淋巴瘤死亡率的相关因素：一项全国住院患者样本分析（2020 - 2021年）
Cureus. 2025 Jun 22;17(6):e86534. doi: 10.7759/cureus.86534. eCollection 2025 Jun.
2
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.免疫功能低下个体对SARS-CoV-2的适应性免疫反应失调。
Microorganisms. 2025 May 6;13(5):1077. doi: 10.3390/microorganisms13051077.
3
Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.

本文引用的文献

1
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究：一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.
2
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
3
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
头颈部癌患者接种新型冠状病毒疫苗后IgG/IgM水平的相关因素
Trop Med Infect Dis. 2024 Oct 8;9(10):234. doi: 10.3390/tropicalmed9100234.
4
Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.免疫检查点抑制剂与实体瘤患者 SARS-CoV-2 感染率和预后的关系：系统评价和荟萃分析。
Front Immunol. 2024 Jun 3;15:1259112. doi: 10.3389/fimmu.2024.1259112. eCollection 2024.
5
Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic: A population-based, nation-wide study.淋巴系统恶性肿瘤和多发性骨髓瘤患者在新冠疫情期间及疫情期间的死亡率保持稳定：一项基于人群的全国性研究。
Hemasphere. 2024 Mar 19;8(3):e57. doi: 10.1002/hem3.57. eCollection 2024 Mar.
6
The Impact COVID-19 Infection on Cancer Patients: A Tertiary Cancer Center Experience in Jordan.新型冠状病毒肺炎感染对癌症患者的影响：约旦一家三级癌症中心的经验
Cureus. 2023 Dec 29;15(12):e51310. doi: 10.7759/cureus.51310. eCollection 2023 Dec.
7
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.细胞因子反应性 T 细胞和 NK 细胞描绘了多发性骨髓瘤患者对 SARS-CoV-2 疫苗的反应和感染情况。
Leukemia. 2024 Jan;38(1):168-180. doi: 10.1038/s41375-023-02070-0. Epub 2023 Dec 4.
8
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.奥密克戎相关的 COVID-19 血液病患者防治措施及血液学治疗方案调整策略。
Front Cell Infect Microbiol. 2023 Oct 19;13:1207225. doi: 10.3389/fcimb.2023.1207225. eCollection 2023.
9
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era.在新冠疫情期间，癌症患者的情况是否比普通人群更糟？一项来自挪威、丹麦和冰岛在疫苗接种前时代的基于人群的研究。
Lancet Reg Health Eur. 2023 Jul 10;31:100680. doi: 10.1016/j.lanepe.2023.100680. eCollection 2023 Aug.
10
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.替沙格韦单抗/西加韦单抗用于血液系统恶性肿瘤患者的新型冠状病毒2型暴露前预防
Front Oncol. 2023 Jun 22;13:1212752. doi: 10.3389/fonc.2023.1212752. eCollection 2023.
血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
4
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.
5
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.无症状或轻症 COVID-19 康复者体内具有强大的 T 细胞免疫。
Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14.
6
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings.对多种 COVID-19 血清学技术的比较评估支持在医院和社区医疗保健环境中继续评估即时护理侧向流动检测。
PLoS Pathog. 2020 Sep 24;16(9):e1008817. doi: 10.1371/journal.ppat.1008817. eCollection 2020 Sep.
7
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London.影响癌症患者新冠病毒病结局的因素：来自伦敦盖伊癌症中心的首份报告
Front Oncol. 2020 Jul 22;10:1279. doi: 10.3389/fonc.2020.01279. eCollection 2020.
8
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19.从严重 COVID-19 的急性期到恢复期的系统免疫监测。
Cell Rep Med. 2020 Aug 25;1(5):100078. doi: 10.1016/j.xcrm.2020.100078. Epub 2020 Aug 5.
9
A dynamic COVID-19 immune signature includes associations with poor prognosis.一个动态的 COVID-19 免疫特征包括与预后不良的关联。
Nat Med. 2020 Oct;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6. Epub 2020 Aug 17.
10
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic.在新型冠状病毒肺炎大流行期间，我们如何管理慢性淋巴细胞白血病患者。
Hemasphere. 2020 Jul 30;4(4):e432. doi: 10.1097/HS9.0000000000000432. eCollection 2020 Aug.